Online citations, reference lists, and bibliographies.
← Back to Search

Peritoneal Mesothelioma: Current Status And Future Directions.

T. Chua, C. H. Chong, D. Morris
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Peritoneal mesothelioma is a rare malignancy where life expectancy with systemic chemotherapy remains poor. Most patients with this disease are diagnosed late with extensive peritoneal disease burden leading to nausea, pain, and abdominal distention as a result of ascites and a partial bowel obstruction. A newly proposed staging system comprising elements of the tumor burden measured by the peritoneal cancer index, abdominal nodal status, and extra-abdominal metastases has been demonstrated to reliably stratify patient outcomes based on staging subgroups after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. This new staging system may form the basis of selecting patients for radical surgery and improve survival outcomes.
This paper references
10.1158/1055-9965.EPI-10-0346
Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma
J. Creaney (2010)
10.1631/jzus.B1000338
Malignant peritoneal mesothelioma presenting with persistent high fever
L. Chen (2011)
10.1038/bjc.1984.254
Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.
P. Canney (1984)
10.1053/HUPA.2001.24329
Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
C. Comin (2001)
Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
D. Baratti (2008)
10.1053/SONC.2002.30236
Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience.
P. Sugarbaker (2002)
10.1158/1078-0432.CCR-05-1477
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
R. Hassan (2006)
10.1136/thx.54.7.638
The molecular basis of asbestos induced lung injury
D. Kamp (1999)
10.1016/j.lungcan.2008.08.013
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.
G. Cartenì (2009)
10.1148/rg.283075082
Neoplastic and nonneoplastic conditions of serosal membrane origin: CT findings.
Y. J. Jeong (2008)
10.1097/COC.0b013e3180684181
Combined Resection, Intraperitoneal Chemotherapy, and Whole Abdominal Radiation for the Treatment of Malignant Peritoneal Mesothelioma
M. Hesdorffer (2008)
10.1177/028418519103200503
Peritoneal Mesothelioma
P. Ros (1991)
10.1093/annonc/mdp307
Malignant peritoneal mesothelioma: a multicenter study on 81 cases.
V. Manzini (2010)
10.1186/1758-3284-3-21
A case report of metastasis of malignant mesothelioma to the oral gingiva
Stephanie Moser (2011)
10.1007/BF01225271
Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma
M. Markman (2005)
10.1111/j.1349-7006.2011.02165.x
National survey of malignant mesothelioma and asbestos exposure in Japan
K. Gemba (2012)
10.1200/JCO.1988.6.1.147
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.
K. Antman (1988)
10.1097/PAS.0b013e3181b6bde3
Tenascin-X is a Novel Diagnostic Marker of Malignant Mesothelioma
Y. Yuan (2009)
10.1177/030089160509100503
Computed Tomographic Characterization of Malignant Peritoneal Mesothelioma
T. Yan (2005)
10.1007/s12199-008-0063-8
Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases
S. Murakami (2009)
10.1007/BF02893422
Subcutaneous metastasis of peritoneal mesothelioma diagnosed by Fine-Needle Aspiration
L. Pappa (2008)
Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma.
B. Laterza (2009)
10.1002/jso.21058
Technical aspects of cytoreductive surgery
S. Kusamura (2008)
10.2214/AJR.138.3.531
CT of peritoneal mesothelioma: analysis of eight cases.
N. Whitley (1982)
10.1200/JCO.1993.11.8.1559
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
A. Chahinian (1993)
10.1097/MCG.0b013e31824e901b
Serum Thioredoxin-1 as a Diagnostic Marker for Malignant Peritoneal Mesothelioma
C. Tabata (2013)
10.1136/thx.2006.068114
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
J. Creaney (2007)
10.1038/modpathol.3800245
Granulocyte-colony stimulating factor- and interleukin 6-producing diffuse deciduoid peritoneal mesothelioma
Noriko Kimura (2005)
10.1002/bjs.7263
Multi‐institutional experience of diffuse intra‐abdominal multicystic peritoneal mesothelioma
T. Chua (2011)
10.1155/2012/492608
Asbestos-Induced Cellular and Molecular Alteration of Immunocompetent Cells and Their Relationship with Chronic Inflammation and Carcinogenesis
H. Matsuzaki (2012)
10.1245/s10434-006-9192-8
Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion
D. Baratti (2006)
Usefulness of tumor marker CA-125 serum levels for the follow-up of therapeutic responses in tuberculosis patients with and without serositis.
W. Huang (2011)
Benign multicystic peritoneal mesothelioma.
N. Uzüm (2009)
10.1378/CHEST.07-0013
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
J. Creaney (2007)
10.1200/JCO.2009.23.9640
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
T. Yan (2009)
10.1200/JCO.2007.15.2868
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
G. Simon (2008)
10.1002/cncr.25640
A novel tumor‐node‐metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi‐institutional database *
T. Yan (2011)
10.1177/030089160509100101
Malignant peritoneal mesothelioma.
Vincenzo De Pangher Manzini (2005)
10.3109/1547691X.2010.512579
Dysregulation of the immune system caused by silica and asbestos
M. Maeda (2010)
10.2214/AJR.07.3628
Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis.
J. Y. Park (2008)
10.2471/BLT.11.086678
Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008.
V. Delgermaa (2011)
10.1158/0008-5472.CAN-04-2461
Evidence against a role for SV40 in human mesothelioma.
J. Manfredi (2005)
10.1289/ehp.1002845
Global Magnitude of Reported and Unreported Mesothelioma
Eun-Kee Park (2011)
10.1245/s10434-009-0756-2
Lymph Node Metastases in Diffuse Malignant Peritoneal Mesothelioma
D. Baratti (2009)
10.1245/s10434-012-2237-2
Cytoreductive Surgery with Selective Versus Complete Parietal Peritonectomy Followed by Hyperthermic Intraperitoneal Chemotherapy in Patients with Diffuse Malignant Peritoneal Mesothelioma: A Controlled Study
D. Baratti (2012)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar